PRECYTE INC — Department of Health and Human Services SBIR Phase I: 102

Description

DESCRIPTION provided by applicant We are developing the Indicator Cell Assay Platform iCAP a broadly applicable and inexpensive blood based assay that can be used for early detection of disease disease stage stratification prognosis and response to therapeutic intervention for a variety of diseases The iCAP uses cultured cells as biosensors capitalizing on the ability of cells to respond differently to signals present in the serum or other biofluid from normal or diseased subjects with exquisite sensitivity as opposed to traditional assays that rely on direct detection of molecules in blood Developing the iCAP involves exposing cultured cells to serum from normal or diseased subjects measuring a global differential response pattern and using it to build a reliable disease classifier comprised of a small number of features Deploying the iCAP involves measuring only expression genes that are features of the disease classifier using cost effective tools Indicator cells are chosen based on the disease application and those typically selected have known relationships to the disease pathology The iCAP can overcome barriers to blood based diagnostics like broad dynamic range of blood components low abundance of specific markers and high levels of noise The focus of this proposal is to initiate development of the iCAP for blood based diagnosis of lung cancer LC Blood biomarkers of LC are desperately needed for use in combination with existing imaging tools to improve diagnostic accuracy Our long term goal is to develop a blood based assay for clinical use on patients that have indeterminate pulmonary nodules identified by imaging to distinguish those with LC from those with benign nodules This assay will help patients with benign nodules avoid invasive biopsy and focus further diagnostic tests on those with LC For this Phase I study we propose to develop an assay to reliably distinguish LC from benign nodules from patient serum samples Specifically we aim to identify optimal indicator cells for the assay develop an iCAP based classifier to reliably distinguish patients with lung cancer from those with benign nodules using patient serum and validate the assay by analyzing new serum samples If we successfully achieve robust classification with andgt blind predictive accuracy and sensitivity and specificity the assay will be optimized and validated with larger cohorts in a Phase II study PUBLIC HEALTH RELEVANCE We are developing a novel blood based diagnostic tool called the indicator cell assay platform iCAP that uses cultured cells as biosensors to detect disease status of patients from blood samples The iCAP will succeed where other methods have failed by exploiting cellsandapos natural capability to amplify and integrate disease signals in blood Here we will initiate development of an assay to robustly identify lung cancer in patients that have indeterminate pulmonary nodules identified by imaging to avoid invasive biopsy and focus further diagnostic test on those with lung cancer